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Highly active antiretroviral therapy (HAART) has significantly improved the outcome and survival of human
immunodeficiency virus (HIV)-infected patients. Subsequently, long-term morbidities including cancer have become
of major public health and clinical interest for this patient population. Plasma cell disorders occur at higher
incidence in HIV-infected patients; however, the molecular mechanisms driving the plasma cell disease process and
the optimal management for these patients remain to be defined. This article provides an up-to-date review of the
characteristics and management of HIV-infected patients with plasma cell disorders. We first present 3 cases of
plasma cell disorders in HIV-infected patients, ranging from polyclonal hypergammaglobulinemia to symptomatic
multiple myeloma. We then discuss the epidemiology, clinical presentation, and management of each of these
plasma cell disorders, with an emphasis on the molecular events underlying the progression of plasma cell diseases
from monoclonal gammopathy to symptomatic multiple myeloma. We propose a three-step hypothesis for the
development of multiple myeloma. Finally, we discuss the use of high dose chemotherapy and autologous
hematopoietic stem cell transplantation in the treatment of HIV-infected patients with multiple myeloma. Our
review includes the care of HIV-infected patients with plasma cell disorders in the current era of HAART and novel
agents available for the treatment of multiple myeloma.
Keywords: HIV, AIDS, Gammopathy, Multiple myeloma, Epidemiology, Molecular mechanism, Treatment, Outcome,
Hematopoietic stem cell transplantationIntroduction
Since the introduction of highly active antiretroviral
therapy (HAART) between late 1996 and early 1997,
the survival of HIV-infected patients has dramatically
improved [1]. In developed countries, most HIV-infected
patients live several decades after their diagnosis. Due to
the effectiveness of broad-spectrum antibiotics and anti-
fungal agents, fewer HIV-infected patients die from life-
threatening opportunistic infections. This improvement
in the long-term survival of HIV-infected patients has
raised public health and clinical awareness of increased
risks of cancer within this population. However, HIV-
infected individuals tend to be excluded from the clinical
trials used to establish current practice guidelines for
cancer treatment. As a result, clinical and therapy out-
come data are extremely scarce for HIV-infected* Correspondence: kangy@musc.edu
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reproduction in any medium, provided the orpatients with cancer. Hematologists and medical oncolo-
gists face with the increasingly difficult challenge of pro-
viding optimal treatment for HIV patients with cancer.
HIV-infected patients have increased risks for plasma cell
disorders [2-6]. Plasma cell disorders in HIV-infected
patients can manifest as polyclonal hypergammaglobuline-
mia, monoclonal gammopathy, or symptomatic multiple
myeloma (MM). Polyclonal hypergammaglobulinemia is
characterized by an increased production of several differ-
ent immunoglobulins and diffusely increased proteins in
the gamma region on serum protein electrophoresis
(SPEP). Monoclonal gammopathy of undetermined signifi-
cance (MGUS) is defined by the presence of a serum
monoclonal protein (M-protein) at a level < 3 g/dl, clonal
bone marrow plasma cells <10%, and the absence of end-
organ damage (lytic bone lesion, anemia, hypercalcemia or
renal failure) related to the proliferative process [7,8]. MM
is a plasma cell malignancy and is characterized by the
presence of M-protein, the infiltration of clonal plasma cells
in the bone marrow (≥10%) and the evidence of end-organtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lecular mechanisms of these plasma cell disorders in HIV-
infected patients has important implications in their care.
In this review article, we first present our experience in
managing three cases of HIV patients with different presen-
tations of plasma cell disorders. We then provide an up-to-
date review of the epidemiology and molecular mechanisms
of plasma cell disorders in HIV-infected patients. We
propose a three-step hypothesis in MM development.
Case presentation
Case 1
A 58-year-old African American female presented with a
three-month history of fatigue, poor appetite, lack of en-
ergy, and 40 lbs weight loss. Her past medical history
was significant for hysterectomy and uncontrolled dia-
betes. Physical examination demonstrated hepatomegaly
with liver palpable 2 fingerbreadths below the right cos-
tal margin. There was no palpable lymphadenopathy.
Laboratory tests showed a white blood cell count (WBC)
of 2.31 × 109/L, hemoglobin 9.4 g/dl, platelet count
281 × 109/L; creatinine 0.8 mg/dl, serum calcium
8.9 mg/dl, total protein 8.2 g/dl, and albumin 2.51 g/dl.
SPEP and immunofixation (IFE) revealed 3.22 g/dl of
broad-based protein band in the gamma zone and
0.73 g/dl of monoclonal immunoglobulin G (IgG)- kappa
(κ) M-protein. Bone skeletal survey showed no lytic
lesions. Bone marrow aspirate and biopsy showed
increased number of plasma cells (15% on biopsy) with
no light chain restriction. HIV screening test was posi-
tive, confirmed with Western blot analysis. The CD4
count was 15/μl and HIV viral load 934,811 copies/ml. She
was diagnosed with HIV-associated polyclonal hypergam-
maglobulinemia with concomitant monoclonal gammopa-
thy. She was referred to the infectious disease clinic and
was started on HAART.
Case 2
A 45-year-old Hispanic male was referred for evaluation
of laboratory finding of hypergammaglobulinemia. Dur-
ing a routine lab test, the patient was found to have a
total protein of 12.6 g/dl and an albumin of 2.4 g/dl. He
was completely asymptomatic. His past medical history
was significant for HIV infection diagnosed more than
two decades ago. He participated in a clinic trial with
HIV gp160 vaccination soon after the diagnosis of HIV
infection, but he had not been on HAART. At the time
of his initial visit in the hematology-oncology clinic, his
CD4 count was 703/μl and his HIV viral load was 933
copies/ml. He had hemoglobin of 10.1 g/dl but serum
calcium and serum creatinine were normal. Serum IgA
level was 332 mg/dl; IgG 7,182 mg/dl; and IgM
2,221 mg/dl. SPEP and IFE exhibited an IgG- κ M-
protein at 3.83 g/dl on a background of polyclonalhypergammaglobulinemia. Urine protein electrophoresis
of 24 h urine (UPEP) revealed excretion of κ light chain
protein at 0.23 g/24 h. Bone marrow aspiration and bi-
opsy showed 32% κ light chain restricted- plasma cells.
Karyotype and Fluorescence In Situ Hybridization
(FISH) analyses of bone marrow cells were normal. His
β2- microglobulin was elevated at 5.3 mg/L. Based on
the presence of anemia, M-protein of 3.83 g/dl and κ
light chain restricted plasmacytosis in the bone marrow,
he was diagnosed with MM. He was started on HAART
with AtriplaW (efavirenz, emtricitabine, and tenofovir).
Subsequently, he was treated with thalidomide plus
dexamethasone. After one cycle, the patient developed
severe neuropathy and thus the chemotherapy was chan-
ged to lenalidomide plus dexamethasone. He was also
on double strength trimethoprim/sulfamethoxazole for
infection prophylaxis and enoxaparin for deep vein
thrombosis (DVT) prophylaxis. He achieved a very good
partial response after 4 cycles of lenalidomide + dexa-
methasone treatment.
Case 3
A 53-year-old Caucasian male presented with a one-
month history of chest wall and back pain, and right-
sided leg weakness and pain. Past medical history was
significant for HIV infection and AIDS diagnosed about
27 years ago. He had a history of cytomegalovirus
(CMV) retinitis, rectal condylomata, and toxoplasmosis,
and he had been taking AtriplaW over the last 2 decades.
His CD4 count had been >1000/μl and HIV viral load
undetectable. Computed tomography (CT) and magnetic
resonance imaging (MRI) studies revealed enhancing
soft tissue lesions involving the posterolateral right 8th
rib and the posterior left 12th rib; fracture of the left
posterior 7th rib; lytic lesions involving the thoracic (T)
4, T12, and lumbar (L)1 vertebral bodies, and a large le-
sion involving the right sacroiliac joint. CT guided
biopsy of the right sacroiliac mass revealed plasma cell
neoplasm with κ light chain restriction. His WBC was
8.65 × 109/L, hemoglobin 12 g/dl, platelet count
433× 109/L, serum creatinine 1.0 mg/dl, albumin 2.6 g/
dl, and serum calcium 10.4 mg/dl. SPEP and IFE demon-
strated an IgG κ M-protein at 1.64 g/dl. Bone marrow
biopsy and aspiration revealed κ light chain restricted-
plasma cells at 10%. FISH analysis showed 1 extra copy
of 1q and a 13q14 deletion. The patient was diagnosed
with MM (Stage III by International Staging System) with
extensive medullary plasmacytoma. He continued his
HAART and was treated with 6 cycles of VCd regimen
(bortezomib, cyclophosphamide and dexamethasone). He
also received a total of 30 Gy fractioned irradiation of the
spine and the iliac crests. Due to the concern of possible
progression in bony lytic lesions, his chemotherapy regimen
was switched to VRd (bortezomib, lenalidomide and
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a very good partial response. Because of the aggressiveness
of his MM, the patient then underwent high dose
chemotherapy and autologous hematopoietic stem cell
transplant (HSCT). He received pegfilgrastin for stem cell
mobilization and successfully collected 8.3 × 106 CD34+
cells/kg body weight with only one-day leukapheresis. He
received high dose melphalan (200 mg/m2) conditioning
and autologous HSCT. His HSCT was relatively uneventful.
He had an appropriate count recovery, and restaging at
3 months post HSCT showed no evidence of M-protein in
SPEP and UPEP.
Discussion
Plasma cell disorders in HIV-infected patients range
from polyclonal hypergammaglobulinemia, to monoclo-
nal gammopathy, to malignant plasma cell neoplasms
such as MM and plasma cell leukemia. Our first case
represented mixed polyclonal hypergammaglobulinemia
and monoclonal gammopathy commonly seen in HIV-
infected patients. Our second and third cases repre-
sented malignant plasma cell neoplasms. We will discuss
each of these presentations focusing on the epidemi-
ology and mechanisms of the diseases.
Epidemiology/incidence
Polyclonal hypergammaglobulinemia
Polyclonal hypergammaglobulinemia is a common find-
ing in HIV-infected patients [3,9,10]. Konstantinopoulos,
et al. performed protein electrophoreses on and mea-
sured immunoglobulin concentrations in the serum
samples of 320 consecutive HIV-infected patients at the
Beth Israel Deaconess Medical Center and found that
1.9% of the HIV-infected patients had polyclonal hyper-
gammaglobulinemia [11].
Monoclonal gammopathy
The incidence of monoclonal gammopathy in HIV-infected
patients appears higher than that in the general population,
where it occurs at 3.2% among persons 50 years of age or
older [12]. In HIV-infected patients, the incidence of mono-
clonal gammopathy ranged from 3.8% to 26% in several
small retrospective studies [3,6,13,14]. Furthermore, com-
pared to the general population, monoclonal gammopathy
in HIV-infected patients occurs at a much younger age.
The mean age of HIV-associated monoclonal gammopathy
has been reported at 34–43 years of age [6,15]. In contrast,
the mean age at diagnosis for MGUS in the general popula-
tion is 70 years [12,16].
Multiple myeloma
There were six large population studies that demon-
strated an increased incidence of MM in HIV/AIDS
(acquired immune deficiency syndrome) patients[17-22]. Two of these studies were performed in the
United States and covered 11 regions in the periods
from 1980 to 1996 (a total of 302,834 AIDS patients)
[17] and from 1996 to 2002 (a total of 375,933 AIDS
patients) [19]. The standardized incidence ratios (SIRs)
for MM for these two periods of time were 2.60
(95% CI: 1.92-3.44) and 2.20 (95% CI: 1.10-3.94),
respectively. Grulich, et al. performed an epidemiological
study of the incidence of cancers in HIV/AIDS patients
in Australia nationwide from 1985 to 1999 [18]. There
were a total of 13,067 HIV/AIDS patients in Australia
during this period of time. The SIR for MM was 4.17
(95% CI: 1.35-9.72). The SIRs for MM in HIV/AIDS
patients in Italy and Switzerland were 4.84 (95% CI:
1.00-14.14) and 5.00 (95% CI: 0.61-18.06), respectively
[20,21]. Using data obtained from the Communicable
Disease Surveillance Centre’s national HIV database and
the Thames Cancer Registry, Newnham, et al. assessed
the risk of cancers in 26,080 HIV-infected people in
southeast England [22]. The SIR was significantly
increased for MM (2.70 with 95% CI: 1.00 – 5.94). Grulich,
et al. then performed a meta-analysis combing all six stud-
ies and found that the SIR for MM in HIV/AIDS patient
was 2.71 with 95% CI of 2.13-3.44 [23]. Similarly, another
meta-analysis also revealed an increased risk of MM in
HIV/AIDS patients: the relative risk of MM in HIV/AIDS
patients was in the range of 1.9 to 6.5 [24].
Mechanisms/etiology
The exact mechanisms for the increased risk of plasma
cell disorders in HIV patients remain poorly understood.
Two main mechanisms likely contribute to the develop-
ment of plasma cell disorders in this patient population:
antigen stimulation and immunodeficiency.
Antigen stimulation
HIV viral antigens and/or other bacterial/viral antigens
may act as super-antigens [3,9,10,25-27] and stimulate
the proliferation of B cells and the secretion of immuno-
globulin without the help of T cells. It is generally
believed that chronic antigenic stimulation is the driving
force for the process. Very little, however, is known
about the nature of the antigen(s), and published data
have been controversial. It was stipulated that viral infec-
tion or viral antigens from HIV per se, Epstein-Barr (EB)
virus, Kaposi’s sarcoma virus, herpes viruses, and hepa-
titis B and C viruses might play an important role in
driving B cell expansion.
HIV viruses/viral antigen The role of HIV viruses or
HIV viral antigens in the clonal expansion of B cells and
the development of MM has been investigated [28,29].
Currently, there is little evidence of the HIV virus play-
ing a direct role in the development of MM.
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infected patients [29], and the monoclonal paraproteins
in HIV-infected patients may be directed against HIV
viral antigens [30-33]. This suggests that HIV viruses
could play a role in the pathogenesis of plasma cell dis-
orders. It should be noted, however, that HIV viruses
can neither infect B cells or plasma cells, nor drive their
malignant transformation [28].
Epstein-Barr virus Voelkerding, et al. reported a case of
aggressive MM in a 31-year-old HIV-infected male pa-
tient presenting with diffuse myeloma infiltration and
hypercalcemia [34]. Interestingly, DNA hybridization
showed the presence of EB virus genomes in myeloma
tissue but not in non-tumor tissue [34]. Additionally,
Kumar, et al. reported 3 cases of MM in young HIV-
positive males, with two of these cases demonstrating a
clonal population that was positive using a probe to the
EB virus terminal repeat region [35]. These small studies
suggest a potential association between MM and EB virus.
However, additional studies are needed to confirm this con-
nection between the EB virus and MM pathogenesis.
Human herpes virus 8 (HHV8) HHV8 is a gamma
herpes virus and causes Kaposi’s sarcoma (KS) in HIV/
AIDS patients. Cannon, et al. examined the correlation
between MM and KS [36]. The authors obtained cancer
incidence and survival data from the US Surveillance,
Epidemiology, and End Results (SEER) program between
1973 and 1995. They found that the vast majority of
MM cases were most likely not associated with KS or
HHV8. Using polymerase chain reaction (PCR) analysis,
HHV8 DNA was found positive in KS biopsies, but not
in MM bone marrow biopsies [37,38]. No antibodies
against HHV8 were found in sera from MM patients
[39-41]. None of these studies support a role for the
HHV8 in the genesis of MM. While the data strongly
support the conclusion that HHV8 is not connected to
the MM pathogenesis, an alternative study conducted by
Chauhan et al., in which the scientists used nested PCR
to detect HHV8 DNA sequences in bone marrow stro-
mal cells from 26 patients with MM, and found that the
majority of these MM patients (92%) had detectable KS
DNA in the long-term bone marrow stromal cells [42].
The implications of Chauhan’s findings are unclear.
Immunodeficiency
HIV viruses can cause T cell dysfunction, and dysfunc-
tional T cells may induce the activation of B cells with-
out the need for antigen stimulation [43]. Additionally,
HIV infection depletes T cells resulting in profound im-
munodeficiency. Grulich, et al. recently performed a meta-
analysis to investigate the role of immunodeficiency in MM
development. The authors compared the incidence ofcancers including MM in HIV/AIDS patients and in kidney
transplant patients receiving immunosuppression [23]. The
authors reasoned that, while both of these populations were
immunosuppressed, kidney transplant patients would differ
substantially from HIV/AIDS patients in lifestyle-related
cancer risk factors. If cancer incidence patterns were similar
between the two populations, then one could conclude that
immune deficiency was primarily responsible for the
increased risks of cancers in HIV/AIDS patients. Indeed,
the authors found that the SIR for MM in HIV/AIDS
patients was 2.71 (95% CI: 2.13-3.44), which was quite simi-
lar to that in renal transplant recipient (SIR: 3.12 and
95% CI: 2/13-4.57). These data suggest that T cell depletion
and immune deficiency may play a key role in the increased
incidence of MM in HIV/AIDS patients.
Molecular mechanisms of myelomagenesis
Recent advancements in molecular biology and cancer
genomics technology have tremendously improved our
understanding of the molecular pathways involved in the
pathogenesis of MM. The development of normal
plasma cells involves 2 main organs: the bone marrow
and the lymph node [44]. In the bone marrow, the com-
mon lymphocyte progenitor cells differentiate into pro-B
cells that undergo immunoglobulin heavy chain (IgH)
gene rearrangement and differentiate into pre-B cells.
Pre-B cells express cytoplasmic mu chains but no sur-
face immunoglobulin due to minimal light chain gene
rearrangement. Once light chains rearrange, surface IgM
can be expressed on immature B cells. These cells mi-
grate out of the bone marrow and into the lymph node
and other peripheral lymphoid tissues. In the lymph
node, the IgM+ B cells encounter antigen (and receive
T-cell help), and then can undergo somatic hypermuta-
tion. After activation, B cells then become either mem-
ory B cells that when encountering the same antigen
mount a rapid and robust immune response or plasma
cells that produce antibodies to bind and neutralize the
antigen. Recent studies suggest that Interferon Regula-
tory Factor 4 (IRF4, also called Mum1) plays an instru-
mental role in the differentiation of B cells into plasma
cells [45]. Once IRF4 is expressed and activated, the
B cells initiate plasmacytic differentiation. Additionally,
IRF4 up-regulates Blimp1 and down-regulates Bcl-6.
The decrease in Bcl-6 and increase in Blimp-1 further
drive B cell differentiation into plasma cells [46].
We hypothesized that the development of MM is a 3-
step process that involves many signaling pathways
(Figure 1). The first step in the MM pathogenesis is the
initiation step, in which normal plasma cells become
malignant myeloma cells. The second step - the expan-
sion step - occurs when malignant myeloma cells inter-
act with bone marrow niche microenvironment(s),
resulting in expansion, proliferation and dissemination
Figure 1 A 3-step working hypothesis for the development of
multiple myeloma. HIV infection contributes to the development
of MM likely through several different mechanisms: 1) HIV infection
increases the risk for somatic hypermutation; 2) HIV infection
activates cell survival pathways; 3) HIV infection alters bone marrow
niche microenvironement; and 4) HIV infection causes persistent
antigen stimulation.
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where a rare population of myeloma stem cells persists
despite currently available treatment. These cells re-
populate, leading to a relapse of the disease. In the fol-
lowing paragraphs, we will review some of the important
molecular mechanisms and pathways that occur during
each of these steps. HIV infection likely has multifaceted
impacts on myelomagenesis (Figure 1).
Step 1: initiation step
How plasma cells become malignant myeloma cells is
not yet fully understood. However, numerous studies
support a two-hit theory in MM development. The first
hit occurs during the process of somatic hypermutation
of B cells in the lymph node. It is postulated that the
first hit results in the transformation from normal
plasma cells to light chain restricted- clonal plasma cells
that cause MGUS. The first hit leads to 2 types of mo-
lecular changes: hyperdiploid change with multiple triso-
mies, or non-hyperdiploid change. The non-hyperdiploid
change commonly involves the translocation of IgH chain
gene at 14q32 with one of the five translocation partners:
cyclin D1 at 11q13; cyclin D3 at 6p21; transcription factor
c-maf at 16q23; fibroblast growth factor receptor (FGFR) 3
and histone methyltransferase MMSET at 4p16; and tran-
scription factor mafB at 20q11 [47,48]. Deletion of chromo-
some 13 is a common non-hyperdiploid change.
After the first hit, the clonal B cells/plasma cells egress
out of the lymph node and circulate in the blood stream
and seed into the bone marrow. In order for the clonal
B cells/plasma cells to become malignant myeloma cells,
there must be a second hit that promotes cell growth
and proliferation. This second hit involves activation of
the myelocytomatosis virus oncogene cellular homolog(c-MYC) pathway, FGFR 3, kirsten rat sarcoma viral
antigen (KRAS) and neuroblastoma (N) RAS pathway,
and nuclear factor (NF)-κB pathway; loss of function in
histone demethylase; activation of toll-like receptor
(TLR) signaling; and stimulation from bone marrow
microenvironment. In this review article, we focus on
c-MYC and NF-κB pathways, TLR signaling, and the
bone marrow microenvironment.
The c-Myc oncogene plays a key role in cell proliferation,
growth, differentiation, and apoptosis [49,50]. c-Myc is dys-
regulated or over-expressed in MM and plays a critical role
in the progression from MGUS to MM [51,52]. The pro-
gression of MGUS to myeloma is associated with several-
fold increase in MYC RNA expression [53]. Overexpression
of MYC leads to the development of myeloma phenotypes
in the Vk*MYC mouse model [54]. Furthermore, targeting
MYC using short hairpin RNA or a selective small mol-
ecule inhibitor of MYC-Max heterodimerization (10058-
F4) induced myeloma cell death [55]. These data suggest
that myeloma cells are addicted to c-MYC activity, and that
c-MYC is indispensable in myeloma development [53].
NF-κB is an important transcription factor that regulates
cell proliferation, angiogenesis, metastasis, inflammation,
and apoptosis [56]. Ni, et al. examined the NF-κB activity in
13 primary myeloma patient samples and in four myeloma
cell lines. NF-κB was constitutively active in all MM patient
samples and in all four myeloma cell lines [57]. Inhibition
of NF-κB induced apoptosis in both primary myeloma cells
and in myeloma cell lines [57]. NF-κB has two signaling
pathways: the classical NF-κB (i.e., RELA/p50 heterodimer)
signaling pathway and the alternative NF-κB (heterodimers
of RELB/p50 and RELB/p52) pathway [58]. Both pathways
can be activated by CD40 and B-cell activating factor. The
classical pathway activates via Iκβα and is involved in innate
immunity, inflammation and cell survival. The alternative
pathway acts through the IκB kinase α (IKKα) and is
involved in lymphoid carcinogenesis, humoral immunity
and B cell maturation. Disruption of NF-κB pathways sensi-
tizes MM cells for apoptosis [59,60].
TLRs recognize pathogen-associated molecular patterns
and are important in innate immunity. TLRs are expressed
and activated in MM and have diverse but contradictory
effects on myeloma cells [61,62]. TLR activation in MM
has important consequences. 1) Myeloma cell growth: TLR
activation induces myeloma cell proliferation, survival and
resistance to drug-induced apoptosis through the activation
of NF-κB and mitogen-activated protein kinase (MAPK)
pathways [63]. 2) Immune evasion. TLR activation can up-
regulate the expression of co-stimulatory molecules and B7
family members through the Myeloid differentiation pri-
mary response gene 88 (MyD88)/TNF receptor associated
factor (TRAF)-6, resulting in tumor evasion from the
immune response [64]. 3). Production of pro-inflammatory
cytokines.TLR activation induces human mononuclear cells
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cytokines including IL-3, IL-6, vascular endothelial growth
factor, basic fibroblast growth factor, hepatocyte growth fac-
tor, macrophage inflammatory protein (MIP)-1α, and the
receptor activator of NF-κB ligand (RANKL) [65]. 4). Up-
regulation of adaptor molecules. TLR activation induces
the expression of most adaptor molecules including
MyD88, TIR-domain-containing adapter-inducing inter-
feron-β (TRIF) and TRAF-6 [66].
Recently, the whole genome or exome of 38 myeloma
patients were sequenced [67]. The frequency of tumor-
specific point mutations was 2.9 per million bases, corre-
sponding to approximately 7,450 point mutations per
sample across the genome. Extensive somatic mutations
were found in MM patients, including mutations of
genes involved in protein translation (seen in nearly half
of the patients), histone methylation, and blood coagula-
tion. In addition, mutations in 11 members of the NF-κB
pathway were found, further supporting the important
role of NF-κB in myeloma pathogenesis [67]. More
recently, Keats, et al. performed genomic analysis on
myeloma cell samples collected at different points
throughout the course of disease of 28 different patients.
They found that the genome of patients with cyto-
genetically high-risk MM tended to show significant
changes over time [68]. Similarly, Egan, et al. conducted
a longitudinal whole-genome sequencing of four tumor
samples collected from a single myeloma patient at vari-
ous stages of the disease and found that the genomic
sequences of the tumor varied as the disease progressed
[69]. Walker, et al. used whole exome sequencing to de-
fine the mutational landscape between t(4;14) and
t(11;14) myeloma patients. The authors found that there
is a distinct mutational landscape in these two groups of
patients, and that each group follows a distinct pathway
[70]. Subsequently, Bahlis proposed a Darwinian-like
somatic evolution in myeloma tumor progression [71].
Step 2: expansion step
During Step two of myeloma pathogenesis, c-Myc, NF-
κB, TLR, KRAS, NRAS, and many other mechanisms
that play a key role in the myeloma initiation step con-
tinue to promote myeloma cell proliferation and
expansion. The interaction between myeloma cells and
the bone marrow microenvironment, which include
bone marrow stromal cells, osteoblasts and osteoclasts,
leads to the expansion of myeloma cells and the mani-
festations of end-organ damages [72-75].
After the first and/or the second hit, myeloma cells up-
regulate the expression of surface adhesion molecules in-
cluding CXCR4, E-cadherin, Integrin α4β1 (also called very
late antigen-4, VLA-4), leukocyte function-associated
antigen-1 (LFA-1), vascular cell adhesion molecule 1
(VCAM-1), intracellular adhesion molecule-1 (ICAM-1),etc. These changes in surface adhesion molecules allow the
myeloma cells to home to the bone marrow microenviron-
ment [76]. Once these myeloma cells enter the bone mar-
row, they adhere to the bone marrow stromal cells through
the interaction of CXCR4/stromal derived factor (SDF)-1,
VLA-4/VCAM-1, LFA-1/ICAM-1, or others. The adhesion
of myeloma cells to the stromal cells prompts the bone
marrow stromal cells to secrete osteoclast-activating factors
(OAFs) such as IL-1β, IL-6, and TNF-β, which further in-
duce stromal cells and osteoblasts to secrete RANKL.
RANKL activates osteoclast progenitors, and the increased
osteoclastic activity leads to release of several cytokines –
such as transforming growth factor-β (TGF-β), IL-6, bFGF,
and insulin-like growth factors – from the bone matrix.
These cytokines directly or indirectly stimulate myeloma
cell growth and cause the MM cells to release parathyroid-
hormone-related protein, which further induces the secre-
tion of RANKL. The end result is a vicious circle, with MM
cells stimulating bone resorption, and bone resorption lead-
ing to increased tumor growth [77].
Myeloma cells also play a critical role in their own ex-
pansion. Myeloma cells secrete Dickkopf-related protein
1 (DKK-1), IL-3, HGF and TGF-β to inhibit osteoblasts,
and they secrete RANKL, TNF, lymphotoxins, SDF-1
and MIP-1α to activate osteoclasts.This inhibition of
osteoblasts and activation of osteoclasts results in
increased levels of bone-derived tumor growth factors
that further promote the expansion and proliferation of
myeloma cells [78]. The direct contact between myeloma
cells and osteoclasts promotes myeloma cell growth [79].
Myeloma cells constantly egress out of bone marrow,
circulate in the blood stream, and reseed back to the
bone marrow, leading to the spread and expansion of
myeloma cells. A recent study by Azab, et al. [80] sug-
gested that hypoxia and epithelial- mesenchymal transi-
tion (EMT) play an important role in this process.
Hypoxia is caused by the growth of myeloma cells in the
bone marrow, and activates EMT-related machinery in
myeloma cells. The EMT transition decreases the ex-
pression of E-cadherin and the adhesion of myeloma
cells to the bone marrow, while leading to the egression
of MM cells into the blood stream. On the other hand,
hypoxia increases the expression of CXCR4, enhances
the homing of circulating myeloma cells to new bone
marrow niches, and results in MM dissemination and
expansion.
Step 3: maintenance step
MM is still considered an incurable disease. Eventually,
almost all patients tend to relapse and develop resistance
to currently available treatment. The Step three in MM
pathogenesis is to maintain the presence of myeloma cell
population likely through 3 mechanisms: 1) Persistent
presence of antigen stimulation to continuously drive
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the marrow niche microenvironment from chemo treat-
ment [81]; and 3) Presence of clonogenic myeloma can-
cer stem cells.
Pilarski, et al. first documented the presence of clono-
genic myeloma cancer stem cells in human MM samples
using serial transplant models in NOD mice [82]. Matsui,
et al. found that the frequency of clonogenic myeloma stem
cells is in the range of ~ 1 in 1,000 to 1 in 100,000 cells
(similar to hematopoietic stem cells). These clonogenic
myeloma cancer stem cells show normal memory B cell
phenotypes (i.e., CD138negCD20+CD27+). Not only are they
resistant to dexamethasone, lenalidomide, and bortezomib
and display Hoechst 33342 side-population stem cell prop-
erties, but they also have significantly higher levels of alde-
hyde dehydrogenase (ALDH) activity and are quiescent
(in G0-G1 resting stage). Furthermore, these cancer stem
cells have the ability to self-renew and differentiate [83,84].
It has been further demonstrated that the hedgehog signal-
ing pathway is critical in maintaining the myeloma cancer
stem cell population [85].
Clinical characteristics
HIV patients with polyclonal hypergammaglobulinemia
commonly present with elevated levels of immunoglobulins
and diffusely increased proteins in the gamma regimen of
SPEP. A bone marrow biopsy is usually not required, but if
performed, these patients show plasmacytosis without light
chain restriction. Patients with monoclonal gammopathy
show a narrow, but distinct protein spike on SPEP and/or
UPEP and may also have a background polyclonal hyper-
gammaglobulinemia. Serum free light chain may also
be elevated in these patients. Most importantly, MGUS
patients show no evidence of end organ damage.
Briault, et al. utilized immunoelectrophoretic analysis
and immunoblotting techniques to characterize the
monoclonal immunoglobulin in HIV-infected patients
[14]. Interestingly, the predominant light chain in HIV-
related monoclonal immunoglobulin was lambda (λ)
type (the κ:λ ratio in the whole series: 0.6). There was
no monoclonal IgA immunoglobulin in this series of
patients. The subclass distribution of monoclonal IgG in
HIV-associated monoclonal gammopathy was different
from that observed in MM patients in the general popu-
lation. HIV-infected patients displayed a much higher
frequency of IgG3 and IgG4 M-proteins, and a much
lower frequency of IgG1 M-proteins. In these patients,
the distribution of monoclonal IgG1, IgG2, IgG3 and
IgG4 were 42.5%, 19%, 23.5%, and 15%, respectively. In
MM patients in general population, the distribution for
IgG1, IgG2, IgG3 and IgG4 were 76.1%, 14.2%, 3.4%, and
6.3%, respectively.
In the general population, MGUS progresses to symp-
tomatic plasma cell neoplasms or lymphoproliferativedisorders at a risk of 0.6 to 3.4 percent/year [86]. The
risk of progression can be stratified using 3 adverse fac-
tors; i.e., the level of serum M-protein, the type of serum
M-protein, and the ratio of serum free light chains
[87,88]. It is unclear if the monoclonal gammopathy seen
in HIV-infected patients may also represent a premalig-
nant clonal plasma cell disorder that can progress to
malignant plasma cell neoplasm. It remains to be deter-
mined if the risk-stratification model used in the general
population for MGUS transformation is applicable in
HIV-infected patients. Lefrere, et al. followed eleven
HIV patients with monoclonal gammopathy over a 6-
year period of time and found that none of these
patients developed an overt plasma cell malignancy or
non-Hodgkin’s lymphoma [13]. Similarly, a smaller study
with only seven HIV patients with monoclonal gammo-
pathy also did not show any progression to NHL or
plasma cell malignancy over a 2–4 year period [33].
However, due to the small patient population and short
follow-up of these studies, more data are needed before
we can draw any definitive conclusions.
MM in HIV/AIDS patients has several unique char-
acteristics. 1) In the general population, MM is a dis-
ease for older adults: the median age at diagnosis is
66 years and only 2 percent of patients are younger
than 40 years [89,90]. For HIV-infected patients, on
the other hand, MM occurs at a much younger age: the
mean age of HIV patients with MM in a series of 35
patients was 42 years [90]. 2) MM in HIV-infected
patients shows an atypical clinical evolution; it tends to
present as solitary bone plasmacytoma or extramedul-
lary plasmacytoma [91]. These patients also tend to
have low level of M-protein despite the aggressiveness
of the disease. Some patients may present as plasma
cell leukemia. 3) The progression of MM in HIV-
infected patients is very rapid and the overall survival
is short. 4) MM in HIV-infected patients shows atyp-
ical histopathological findings, and some patients may
present with anaplastic features. These anaplastic mye-
loma cells are negative for the common leukocyte anti-
gen, lysozyme, and the cytoplasmic immunoglobulins.
Anaplastic MM can present as the first manifestation
of AIDS [92,93]. 5) MM in HIV-infected patients tends
to occur in anal sex patients. 6) Elevated serum LDH
level correlate with a poorer outcome in HIV/AIDS
patients with MM.
The interval between HIV infection and diagnosis of
MM remains to be determined. In both our patients, MM
was diagnosed more than 2 decades after HIV infection
(Case 3 developed AIDS, and case 2 did not have AIDS).
It is important to note that there have also been reports of
MM as the first presentation of HIV/AIDS [92]. There-
fore, it appears that MM occurs at various stages of HIV
infection: some patients develop MM during the early
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The management of plasma cell disorders in HIV-
infected patients is quite similar to that in the general
population. For HIV-infected patients with polyclonal
hypergammaglobulinemia and monoclonal gammopathy,
the current standard of care is close follow-up and
HAART if indicated. For HIV-infected patients with
symptomatic MM, the appropriate management is to
initiate chemotherapy and continue on HAART.
The hallmark of MM is the existence of end-organ
damage (i.e., hypercalcemia, renal insufficiency, anemia,
or bone lytic lesions), which distinguishes symptomatic
MM from smoldering MM and MGUS [94]. Because
HIV infection or HAART can also cause anemia or renal
insufficiency, we find it important to ascertain the causes
for anemia and renal insufficiency in these patients. In
our practice, we usually consider punched out lytic le-
sion and hypercalcemia relatively unique to MM. For
anemia and renal insufficiency, we usually pursue
additional workup to determine the underlying cause(s)
before we initiate chemotherapy.
HAART
HAART is important in the management of plasma cell
disorders in HIV-infected patients. There are limited
data that suggest that a good response to HAART may
lead to M-protein reduction in some HIV-infected
patients with monoclonal gammopathy [95]. For in-
stance, nine out of 25 patients had a decrease in serum
M-protein level while receiving HAART [15]. Polyclonal
hypergammaglobulinemia may resolve in some patients
after HAART [96]. However, it remains to be deter-
mined if HAART treatment will delay the progression
from monoclonal gammopathy to an overt plasma cell
malignancy [97].
HAART was introduced to developed countries be-
tween late 1996 and early 1997. Thus, the effects of
HAART in the incidence of MM in HIV/AIDS patients
could be potentially determined by comparing the SIRs
before 1996 and after 1996. Frisch, et al. examined the
SIRs of MM in 302,834 AIDS patients during the period
from 1980 to 1996. The SIRs were calculated between
60 months before the development of AIDS and
27 months after AIDS. The SIR for MM from 1980 to
1996 was 2.60 (95% CI: 1.92 -3.44) [17]. In a follow-up
study covering the same regions of population, Engels,
et al. examined the SIRs of MM from 1996 to 2002.
There were a total of 375,933 AIDS patients and the
SIRs were calculated between 4 to 27 months after
AIDS. The SIR for MM from 1996 to 2002 was 2.20(95% CI: 1.00-3.94) [19]. These two studies comparing
the SIRs before and after 1996 suggest a possible positive
impact of HAART on the incidence of MM in HIV/
AIDS patients. However, this impact appears moderate
and suggests that HAART per se does not eliminate the
occurrence of MM in HIV-infected patients.
In our own practice, all HIV-infected patients with
MM who have not been on HAART are referred to the
infectious disease service as soon as possible to initiate
HAART prior to chemotherapy. HAART is initiated re-
gardless of the patient’s history of opportunistic infection
or CD4 count. For instance, our patient #2 had a CD4
count of 703/μl with no history of opportunistic infec-
tion; he was started on HAART prior to initiation of
chemotherapy because of the risks for further immuno-
suppression and bone marrow suppression. The exact
effects of HAART on myeloma outcome remain to be
determined. There have been reports that HAART alone
can lead to the complete remission of smoldering mul-
tiple myeloma [98]. However, these reports have been
unconfirmed. It is also unclear how long the patients
need to be on HAART before chemotherapy is initiated.
Our patient (case#2) started chemotherapy almost im-
mediately after the initiation of HAART. For HIV/AIDS
patients with MM who have been on HAART, we con-
tinue HAART throughout the course of chemotherapy.
It was recently reported that protease inhibitors – such
as ritonavir, saquinavir, and nelfinavir (but not indinavir) -
induced growth cell arrest and apoptosis in several human
myeloma cell lines as well as in primary myeloma cells.
These protease inhibitors down-regulate the antiapoptotic
protein Mcl-1, block interleukin-6-stimulated phosphoryl-
ation of STAT3, and inhibit production of vascular endo-
thelial growth factor [99]. Nelfinavir has synergistic effects
with bortezomib on the proteotoxic death of myeloma cells
[100]. These data support our belief that all the HIV-
infected patients with MM should be on HAART during
chemotherapy.
Chemotherapy for MM
Clinical data on MM in HIV/AIDS patients are sparse and
do not allow for detailed evaluation of therapy or the out-
come of treatment on disease-free survival or overall sur-
vival. Furthermore, most HIV-positive patients with MM
are excluded from clinical trials. There is currently a lack of
well-supported practice guidelines for managing this spe-
cific population of patients. The treatment for HIV-infected
patients with MM is largely extrapolated from data
obtained from the HIV-negative population of patients.
Chemotherapy regimens for MM in HIV-infected
patients are the same as those for HIV-negative MM
patients, and usually consist of 2 to 3 drug combinations of
thalidomide, lenalidomide, bortezomib, and dexamethasone
[101]. The regimens we used for HIV-infected MM are: Td
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methasone), Vd (bortezomib + dexamethasone), VRd
(bortezomib + lenalidomide + dexamethasone), and VCd
(bortezomib + cyclophosphamide + dexamethasone). The
dosing regimens and adjunctive treatment follow the
NCCN recommendations and guidelines. For instance,
DVT prophylaxis is used along with regimens consisting of
thalidomide or lenalidomide. Herpes zoster prophylaxis
with acyclovir is used in regimens with bortezomib.
Aboulafia, et al. reported a combination of thalido-
mide, dexamethasone, and clarithromycin for the treat-
ment of an HIV-associated MM patient. The regimen
led to a rapid and dramatic antitumor effect with modest
regimen-related toxicities. The patient retained a normal
CD4 count and a non-detectable HIV viral load. Due to
the purported immunologic benefit of thalidomide, the
author proposed further evaluation of thalidomide-based
regimens in the treatment of HIV-positive myeloma
patients [102]. Elira Dokekias, et al. reported using
VMCP and VAMCP regimens for the treatment of HIV-
positive myeloma patients. The regimens were well tol-
erated without major complications [103]. In our center,
we have adopted a uniform treatment regimen (i.e., VCd:
bortezomib + cyclophosphamide + dexamethasone) for
all newly diagnosed MM patients and we have achieved
~95% overall response rate [104].
Autologous hematopoietic stem cell transplantation (HSCT)
The role of autologous HSCT in HIV-positive MM
patients is unclear. There have been reports of high dose
chemotherapy and autologous HSCT for MM in HIV-
infected patients. For instance, Kentos, et al. reported
one case of autologous CD34-positive blood HSCT for
an AIDS patient with MM [105]. The patient had suc-
cessful stem cell mobilization and collection and toler-
ated the transplant uneventfully with appropriate stem
cell engraftment. Unfortunately, the patient died one
year post transplant due to relapse of his MM [105].
This case report demonstrates the feasibility of high dose
chemotherapy and autologous HSCT in HIV-infected
myeloma patients. Gorschluter, et al. performed a retro-
spective study measuring CD4+ lymphocyte counts after
autologous HSCT and found that opportunistic infection
was rare post HSCT in HIV-infected myeloma patient
population [106]. Our case #3 proceeded with high dose
melphalan conditioning and autologous HSCT after
achieving a very good partial response from induction
chemotherapy. He achieved appropriate engraftment of
all cell lineages after HSCT and showed no evidence of
M-protein on SPEP and UPEP three months post HSCT.
These data suggest that given the aggressive nature of
MM in HIV-infected patients, high dose chemotherapy
and autologous HSCT should be considered in young
patients with good performance status.Conclusion
Plasma cell disorders occur at an increased frequency in
HIV-infected patients and range from polyclonal hyper-
gammaglobulinemia to aggressive MM. The develop-
ment of MM involves diverse molecular mechanisms
and pathways, and understanding these pathways has
important implications in the treatment of MM in gen-
eral. The widespread use of novel therapeutic agents and
the incorporation of high dose chemotreatment followed
by autologous HSCT have improved the outcome of
patients with MM. However, the effects of these treat-
ment options in HIV-infected MM patients remain to be
determined.
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